thalidomide has been researched along with Stroke in 10 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Stroke: A group of pathological conditions characterized by sudden, non-convulsive loss of neurological function due to BRAIN ISCHEMIA or INTRACRANIAL HEMORRHAGES. Stroke is classified by the type of tissue NECROSIS, such as the anatomic location, vasculature involved, etiology, age of the affected individual, and hemorrhagic vs. non-hemorrhagic nature. (From Adams et al., Principles of Neurology, 6th ed, pp777-810)
| Excerpt | Relevance | Reference |
|---|---|---|
| "We presented a patient suffered from stroke related to thalidomide therapy." | 8.84 | [Brief report: stroke in multiple myeloma patient treated with thalidomide]. ( Hashimoto, Y; Hirano, T; Ito, Y; Mori, A; Uchino, M; Yonemura, K, 2007) |
| "Apremilast (APR) is a selective inhibitor of phosphodiesterase-4 involved in various neurological diseases, including stroke." | 5.72 | Apremilast exerts protective effects on stroke outcomes and blood-brain barrier (BBB) dysfunction through regulating Rho-associated protein kinase 2 expression. ( Cheng, Z; Meng, X; Wang, M, 2022) |
| "β-thalassemia major is a hereditary anemia resulting from defects in β-globin production." | 5.46 | Thalidomide-induced Stroke in a Child With Thalassemia Major. ( Gunaseelan, S; Prakash, A, 2017) |
| "We presented a patient suffered from stroke related to thalidomide therapy." | 4.84 | [Brief report: stroke in multiple myeloma patient treated with thalidomide]. ( Hashimoto, Y; Hirano, T; Ito, Y; Mori, A; Uchino, M; Yonemura, K, 2007) |
| " The objective of this study was to quantify the risk of myocardial infarction (MI), stroke and revascularizations in people with apremilast-treated PsA compared with patients receiving other PsA treatments." | 4.02 | The risks of major cardiac events among patients with psoriatic arthritis treated with apremilast, biologics, DMARDs or corticosteroids. ( Hagberg, KW; Jick, S; Persson, R; Qian, Y; Vasilakis-Scaramozza, C, 2021) |
| "Apremilast (APR) is a selective inhibitor of phosphodiesterase-4 involved in various neurological diseases, including stroke." | 1.72 | Apremilast exerts protective effects on stroke outcomes and blood-brain barrier (BBB) dysfunction through regulating Rho-associated protein kinase 2 expression. ( Cheng, Z; Meng, X; Wang, M, 2022) |
| "Tuberculous meningitis is a highly morbid, often fatal disease." | 1.48 | Intracranial tuberculous mass lesions treated with thalidomide in an immunocompetent child from a low tuberculosis endemic country: A case report. ( Ajassa, C; Caraffa, E; Ciardi, MR; Lichtner, M; Massetti, AP; Mastroianni, CM; Russo, G; Vita, S; Vullo, V, 2018) |
| "β-thalassemia major is a hereditary anemia resulting from defects in β-globin production." | 1.46 | Thalidomide-induced Stroke in a Child With Thalassemia Major. ( Gunaseelan, S; Prakash, A, 2017) |
| "Patients with multiple myeloma (MM) are at increased risk of arterial thrombosis." | 1.43 | Spectrum of Cerebrovascular Disease in Patients with Multiple Myeloma Undergoing Chemotherapy-Results of a Case Control Study. ( Hinduja, A; Limaye, K; Papanikolaou, X; Ravilla, R; Sasapu, A; Torbey, M; Waheed, S; Wei, L, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (10.00) | 29.6817 |
| 2010's | 5 (50.00) | 24.3611 |
| 2020's | 4 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, M | 1 |
| Meng, X | 1 |
| Cheng, Z | 1 |
| Persson, R | 2 |
| Hagberg, KW | 2 |
| Qian, Y | 2 |
| Vasilakis-Scaramozza, C | 2 |
| Jick, S | 2 |
| Cornell, RF | 1 |
| Goldhaber, SZ | 1 |
| Engelhardt, BG | 1 |
| Moslehi, J | 1 |
| Jagasia, M | 1 |
| Harrell, S | 1 |
| Rubinstein, SM | 1 |
| Hall, R | 1 |
| Wyatt, H | 1 |
| Piazza, G | 1 |
| Gunaseelan, S | 1 |
| Prakash, A | 1 |
| Caraffa, E | 1 |
| Russo, G | 1 |
| Vita, S | 1 |
| Lichtner, M | 1 |
| Massetti, AP | 1 |
| Mastroianni, CM | 1 |
| Vullo, V | 1 |
| Ciardi, MR | 1 |
| Ajassa, C | 1 |
| Yoon, JS | 1 |
| Lee, JH | 1 |
| Tweedie, D | 1 |
| Mughal, MR | 1 |
| Chigurupati, S | 1 |
| Greig, NH | 1 |
| Mattson, MP | 1 |
| Hinduja, A | 1 |
| Limaye, K | 1 |
| Ravilla, R | 1 |
| Sasapu, A | 1 |
| Papanikolaou, X | 1 |
| Wei, L | 1 |
| Torbey, M | 1 |
| Waheed, S | 1 |
| Tannemaat, MR | 1 |
| Vries, EP | 1 |
| Molendijk, WJ | 1 |
| Haan, J | 1 |
| Ito, Y | 1 |
| Mori, A | 1 |
| Yonemura, K | 1 |
| Hashimoto, Y | 1 |
| Hirano, T | 1 |
| Uchino, M | 1 |
1 review available for thalidomide and Stroke
| Article | Year |
|---|---|
[Brief report: stroke in multiple myeloma patient treated with thalidomide].
Topics: Aged; Anticoagulants; Aspirin; Embolism, Paradoxical; Foramen Ovale, Patent; Humans; Male; Multiple | 2007 |
1 trial available for thalidomide and Stroke
| Article | Year |
|---|---|
Primary prevention of venous thromboembolism with apixaban for multiple myeloma patients receiving immunomodulatory agents.
Topics: Aged; Comorbidity; Consolidation Chemotherapy; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Imm | 2020 |
8 other studies available for thalidomide and Stroke
| Article | Year |
|---|---|
Apremilast exerts protective effects on stroke outcomes and blood-brain barrier (BBB) dysfunction through regulating Rho-associated protein kinase 2 expression.
Topics: Animals; Blood-Brain Barrier; Brain Ischemia; Claudin-5; Cyclic Nucleotide Phosphodiesterases, Type | 2022 |
The risk of myocardial infarction, stroke, and revascularization among patients with psoriasis treated with apremilast compared with biologics and disease-modifying antirheumatic drugs: A cohort study in the US MarketScan database.
Topics: Age Factors; Aged; Antirheumatic Agents; Biological Products; Drug Therapy, Combination; Female; Fol | 2020 |
The risks of major cardiac events among patients with psoriatic arthritis treated with apremilast, biologics, DMARDs or corticosteroids.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, P | 2021 |
Thalidomide-induced Stroke in a Child With Thalassemia Major.
Topics: beta-Thalassemia; Blood Coagulation Tests; Brain; Child; Combined Modality Therapy; Female; Humans; | 2017 |
Intracranial tuberculous mass lesions treated with thalidomide in an immunocompetent child from a low tuberculosis endemic country: A case report.
Topics: Antitubercular Agents; Brain; Cerebrospinal Fluid; Child; Female; Glucocorticoids; Humans; Hydroceph | 2018 |
3,6'-dithiothalidomide improves experimental stroke outcome by suppressing neuroinflammation.
Topics: Animals; Anti-Inflammatory Agents; Blood-Brain Barrier; Brain Infarction; Cell Death; Cytokines; Dis | 2013 |
Spectrum of Cerebrovascular Disease in Patients with Multiple Myeloma Undergoing Chemotherapy-Results of a Case Control Study.
Topics: Acute Kidney Injury; Antineoplastic Agents; Case-Control Studies; Cerebral Hemorrhage; Hospital Mort | 2016 |
Fatal ischemic stroke in a patient receiving lenalidomide for multiple myeloma.
Topics: Anticoagulants; Antineoplastic Agents; Coma; Fatal Outcome; Female; Heparin, Low-Molecular-Weight; H | 2011 |